ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and rituximab"

  • Abstract Number: 602 • 2015 ACR/ARHP Annual Meeting

    Efficacy of Very Low Dose (100mg) Rituximab in Active Rheumatoid Arthritis Despite Combination DMARD-Single Center, Prospective, Observational Study

    Padmanabha Shenoy1 and Manish Bavaliya2, 1Dept. of rheumatology and clinical immunology, Amrita Institute of medical science and research institute, Kochi, India, 2Department of rheumatology and clinical immunology, Amrita institute of medical sciences and research institute, Kochi, India

    Background/Purpose: Rituximab is an anti-CD20 antibody that represents a therapeutic alternative for the patients with rheumatoid arthritis. It has been proven that rituximab at a…
  • Abstract Number: 603 • 2015 ACR/ARHP Annual Meeting

    Which Seronegative RA Patients Respond to Rituximab? – Preliminary Analysis of a Merged Clinical Trials Dataset

    Elizabeth M.A. Hensor1,2, Edward M. Vital1,2 and Paul Emery1,2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Seronegative RA patients have inferior clinical response to rituximab [1].  However, there is significant heterogeneity in this group of patients for baseline clinical features…
  • Abstract Number: 751 • 2015 ACR/ARHP Annual Meeting

    Rituximab Induced Serum Sickness: A Systematic Review

    Paras Karmacharya1, Dilli Poudel1, Ranjan Pathak1, Anthony Donato2, Sushil Ghimire1, Smith Giri3, Madan Aryal1 and Clifton O. Bingham III4, 1Internal Medicine, Reading Health System, WEST READING, PA, 2Internal medicine, Reading Health System, WEST READING, PA, 3Internal medicine, University of Tennessee Health Science Center, Memphis, TN, 4Rheumatology, Johns Hopkins University, Baltimore, MD

    Background/Purpose: Rituximab (anti-CD20 monoclonal antibody) has been frequently used to treat various autoimmune diseases in which B-cells are participants, and for hematological malignancies in which…
  • Abstract Number: 1040 • 2015 ACR/ARHP Annual Meeting

    Factors Associated with Long Term Rituximab Use in Rheumatoid Arthritis – Results from the British Society of Rheumatology Biologics Register

    Alexander G.S. Oldroyd1, Deborah P.M. Symmons1, Lianne Kearsley-Fleet1, Kath Watson1, Mark Lunt2, Jamie Sergeant1, Kimme L. Hyrich1 and on behalf of the BSRBR-RA, 1Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 2Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Analysis of long term continuation of biologics in rheumatoid arthritis (RA) is considered a valid surrogate for treatment effectiveness and safety. Only a small…
  • Abstract Number: 1569 • 2015 ACR/ARHP Annual Meeting

    Rituximab Efficacy in the Treatment of Diffuse Interstitial Lung Disease Associated with Rheumatoid Arthritis

    Javier Narváez1, Milagros Ricse2, Juan José Alegre3, Gloria Albert Espi3, Carmen Gomez Vaquero4, Helena Borrell Paños2, Eulalia Armengol2, Joan Miquel Nolla2, Susana Herrera5 and Maria Molina6, 1Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, 4Department of Rheumatology, Hospital Universitario Bellvitge, Barcelona, Spain, 5Deparment of Pneumology, Hospital Universitario Dr Peset, Valencia, Spain, 6Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain

    Background/Purpose: To investigate the efficacy and safety of rituximab (RTX) in the the management of progressive rheumatoid arthritis related interstitial lung disease (RA-ILD). Methods: An…
  • Abstract Number: 2093 • 2014 ACR/ARHP Annual Meeting

    Improvement of Rituximab Response Prediction in Rheumatoid Arthritis Via Correction for Prednisone-Related Suppression of Type I Interferon Response Gene Expression

    Tamarah D. de Jong1, Saskia Vosslamber1, Marjolein Blits1, Gertjan Wolbink2, Michael T. Nurmohamed2,3, Connie J. van der Laken4, Gerrit Jansen5, Alexandre E. Voskuyl5 and Cornelis L. Verweij6, 1Pathology, VU University Medical Center, Amsterdam, Netherlands, 2Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 3VU University Medical Center, Amsterdam, Netherlands, 4Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 5Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 6Pathology and Rheumatology, VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose Elevated type I IFN response gene (IRG) expression has been described to be clinically relevant in predicting the non-response to rituximab in rheumatoid arthritis…
  • Abstract Number: 1525 • 2014 ACR/ARHP Annual Meeting

    Cumulative Clinical  Response in  Rheumatoid  Arthritis Patients with  Rituximab Repeated Courses after Failure to Tumor Necrosis Factor Inhibitors in Routine Clinical Practice  

    Catalin Codreanu1, Ruxandra Ionescu2, Ioan Ancuta3, Corina Mogosan4, Simona Rednic5, Paulina Ciurea6, Maria Suta7, Magda Parvu8, Andra Balanescu2, Mihai Bojinca3, Dan Nemes9, Codrina Ancuta10 and Elena Rezus11, 15 Thomas Masaryk Street, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, 2Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, 3Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania, 4'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, 5Rheumatology, University of Medicine and Pharmacy, Cluj-Napoca, Romania, 6Clinical County Hospital,Craiova, Craiova, Romania, 7317 Tomis Str. , Bl. 4A, ap. 3, Constanta Municipal Hospital, Constanta, Romania, 8Rheumatology, Colentina Clinical Hospital, Bucuresti, Romania, 9Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, 10G.T.Popa Center for Biomedical Research, Iasi, Romania, 11Rheumatology, Recovering Clinical Hospital, Iasi, Romania

    Background/Purpose The concept of achieving tight control of rheumatoid arthritis (RA) and treating to target has been well established. It focuses on early diagnosis, aggressive…
  • Abstract Number: 1539 • 2014 ACR/ARHP Annual Meeting

    Relation Between Number of Previous Anti TNF Agents and Clinical Response in Rheumatoid Arthritis Patients Treated with Rituximab

    Daniela Opris1, Diana Mazilu2, Violeta Bojinca3, Andreea Borangiu2, Andra Balanescu4, Denisa Predeteanu5 and Ruxandra Ionescu4, 153 Tineretului Blvd, Bl. 65, s, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, 2Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, 3Intr. Carol Knappe Nr. 9A, Sec, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, 4Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, 5Bld.Mircea Voda Nr 36., Bl M6,, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania

    Background/Purpose Debate is still ongoing regarding rituximab (RTX) as a first or second line biologic therapy. The objective of present study is to assess correlations between…
  • Abstract Number: 1538 • 2014 ACR/ARHP Annual Meeting

    Sustained Clinical Benefit with Multiple Courses of Rituximab in Second Line  for  All Rheumatoid Arthtritis Patients  Irrespective to the Inhibitor of Tumour Necrosis Factor  Previously Used

    Ioan Ancuta1, Ruxandra Ionescu2, Catalin Codreanu3, Andra Balanescu2, Elena Rezus4, Maria Suta5, Paulina Ciurea6, Mihaela Milicescu7, Dan Nemes8, Codrina Ancuta9, Mihai Bojinca10, Magda Parvu11 and Horatiu Popoviciu12, 1“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, 2Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, 35 Thomas Masaryk Street, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, 4Rheumatology, Recovering Clinical Hospital, Iasi, Romania, 5317 Tomis Str. , Bl. 4A, ap. 3, Constanta Municipal Hospital, Constanta, Romania, 6Clinical County Hospital,Craiova, Craiova, Romania, 7Rheumatology, "Dr. I. Cantacuzino" Clinical Hospital, Bucharest, Romania, 8Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, 9G.T.Popa Center for Biomedical Research, Iasi, Romania, 10Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, 11Rheumatology, Colentina Clinical Hospital, Bucuresti, Romania, 12Rheumatology, University of Medicine and Pharmacy Targu Mures, Tg Mures, Romania

    Background/Purpose: In the last decade, biologic therapy changed dramatically treatment options for rheumatoid arthritis (RA). However, a significant number of patients failed to maintain the…
  • Abstract Number: 1508 • 2014 ACR/ARHP Annual Meeting

    Impact of Anti-Drug Antibody on Efficacy and Safety over Week 24 in Both CT-P10 and Innovator Rituximab Treatment Groups

    Dae-Hyun Yoo1, Won Park2, Slawomir Jeka3, Fidencio Cons Molina4, Pawel Hrycaj5, Piotr Wiland6, Wolfgang Spieler7, Eun Young Lee8, Francisco G. Medina-Rodriguez9, Pavel Shesternya10, Sebastiao Radominski11, Dong Hyuk Sheen12, Mie Jin Lim13, Jung-Yoon Choe14, Leysan Myasoutova15, Taek Kwon16, Sang Joon Lee16, Seung-Cheol Shim17 and Chang-Hee Suh18, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, 3University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, 4Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, 5Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, 6Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, 7Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, 8Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 9Centro de Investigación Farmacológica y Biotecnológica, Mexico City, Mexico, 10Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, 11CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, 12Rheumatology, Eulji University Hospital, DaeJeon, South Korea, 13Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, 14Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, 15City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, 16CELLTRION, Inc., Incheon, South Korea, 17Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, 18Allergy-Rheumatology, Ajou University Hospital, Suwon, South Korea

    Background/Purpose CT-P10 is a biosimilar candidate for rituximab. Pharmacokinetic equivalence and similarity of clinical efficacy, safety and immunogenicity had been demonstrated between CT-P10 and Innovator…
  • Abstract Number: 1502 • 2014 ACR/ARHP Annual Meeting

    A Phase I Trial Comparing PF-05280586 (A Potential Biosimilar) and Rituximab in Subjects with Active Rheumatoid Arthritis

    Jean-Claude P. Becker1, Donghua Yin2, Lisa Ann Melia3, Ruifeng Li4, Barry Gumbiner5, Dolca Thomas6, George Spencer-Green7 and Xu Meng2, 1Pfizer Biosimilars Research and Development/Medical Affairs., Pfizer Inc., New York, NY, 2Clinical Pharmacology/Pharmacometrics, Pfizer Inc., San Diego, CA, 3Biotechnology Clinical Development, Pfizer Inc., San Diego, CA, 4Biostatistics, Pfizer Inc., Cambridge, MA, 5Worldwide Research and Development, Pfizer Inc., San Diego, CA, 6Biosimilars Research and Development Unit, Pfizer Inc., New York, NY, 7Worldwide Research and Development, Pfizer Inc., Cambridge, MA

    Background/Purpose: PF-05280586, a proposed biosimilar to rituximab, has the same primary amino acid sequence as rituximab with similar physicochemical and in vitro functional properties. This…
  • Abstract Number: 1419 • 2014 ACR/ARHP Annual Meeting

    Rituximab Use in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease and Other Connective Tissue Disease-Associated Interstitial Lung Disease: A Single Center Experience

    Sandra Chartrand1,2, Jeffery J. Swigris3, Lina Peykova2 and Aryeh Fischer4, 1Rheumatology, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada, 2Rheumatology, National Jewish Health, Denver, CO, 3Autoimmune Lung Center, National Jewish Health, Denver, CO, 4Rheumatology / ILD Program, National Jewish Health, Denver, CO

    Background/Purpose: Small series have suggested that rituximab (RTX) may be effective as rescue-therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD). We sought to describe…
  • Abstract Number: 991 • 2014 ACR/ARHP Annual Meeting

    The Alternative CD20 Transcript Variant Is Not a Factor for Resistance to Rituximab in Patients with Rheumatoid Arthritis

    Cecile Gamonet1, Marina Deschamps2, Sandrine Marion3, Philippe Saas4, Gilles Chioccha3, Christophe Ferrand4 and Eric Toussirot5,6, 1INSERM UMR1098, Etablissement Français du Sang / Université de Franche Comté, Besançon, France, 2INSERM UMR1098 / Etablissement Français du Sang/ Université de Franche Comté, Besançon, France, 3Chronic Inflammation and Immune System Labex Inflamex, Université Versailles Saint Quentin, Montigny le Bretonneux, France, 4Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France, 5Clinical Investigation Centre Biotheraoy CIC 1431, Rheumatology Department, Univesity Hospital, besancon, France, 6Rheumatology, University hospital, Besançon, France

    Background/Purpose: the identification of predictive factors for the response, or alternatively factors for resistance to biological agents is a relevant goal in the management of…
  • Abstract Number: 844 • 2014 ACR/ARHP Annual Meeting

    Frequency of Significant Infection in Patients with RA Following Initiation of Rituximab with up to 5 Years of Follow-up in a US Observational Study

    Kenneth G. Saag1, Kevin L. Winthrop2, Daniel E. Furst3, Kimberly Alexander4, Angelika Jahreis5, Carol Chung6 and Kurt Oelke7, 1Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 2Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, 3University of California at Los Angeles, Los Angeles, CA, 4Epidemiology, Genentech, Inc., South San Francisco, CA, 5Genentech, South San Francisco, CA, 6Genentech, Inc, South San Francisco, CA, 7Rheumatic Disease Center, Glendale, WI

    Background/Purpose: Rituximab (RTX) is an approved treatment for rheumatoid arthritis (RA) in patients (pts) with an inadequate response to anti–TNF therapy (aTNF-IR). Long-term infection risk…
  • Abstract Number: 2928 • 2014 ACR/ARHP Annual Meeting

    Serum IL-33 Level Is Increased in Rheumatoid Arthritis and Predicts Response to Rituximab in Combination with High Serum IgG Level and Autoantibody Positivity: An Open-Label, Prospective, Multicentre Biological Trial

    Jérémie Sellam1, Houria Chavez2, Stéphanie Rouanet3, Nathalie Vernet3, Bineta Ly4, Sandrine Marion-Thore5, Bernard Combe6, Jean Sibilia7, Jacques Tebib8, Gilles Chiocchia9, Maxime Dougados10, Yassine Taoufik2 and Xavier Mariette11, 1AP-HP, Saint-Antoine Hospital, Rheumatology Department and DHU i2B, Paris, France, 2Biologic Immunology, Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, 3Biostatistics, Roche France, Boulogne-Billancourt, France, 4INSERM U1012, Universite Paris-Sud, Kremlin Bicetre, France, 5INSERM U1016, Université Versailles Saint-Quentin, Montigny le Bretonneux, France, 6Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 7Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, 8Rheumatology, University Hospital Lyon, Lyon, France, 9Université Versailles-Saint Quentin, Montigny le Bretonneux, France, 10INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, 11rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France

    Background/Purpose .  The recent discovered cytokine interleukin-33 (IL33) could be involved in B-cell activation as well as in RA pathophysiology. After a whole-blood transcriptomic analysis…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology